Ran Reshef, MD
Hematology · New York, NYNPI 1568659431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $300,736 of the $468,322 with a category attached, or 64.2%. Gilead accounts for 90.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $150,424 and has fallen 58.4% since, to $62,603 in 2025. Among hematology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $1272.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$424K
- Sanofi$10K
- Incyte Corporation$7K
- Novartis$7K
- Johnson & Johnson$6K
- Sanofi-aventis U.S. LLC$5K
- plus $10K from 14 others
Across 237 payments — averaging $20,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$2.6M
- Gilead$1.3M
- Janssen Research & Development, LLC$409K
- Takeda Pharmaceuticals U.S.A., Inc.$298K
- Incyte Corporation$187K
- Genentech, Inc.$99K
- plus $84K from 4 others
What the payments were for
- Consulting fees$106,16823%
- Speaking & faculty fees$300,73664%
- Travel & lodging$55,09312%
- Food & beverage$5,6701%
- Education$6550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 326 | $423,688 |
| Sanofi | 3 | $9,809 |
| Incyte Corporation | 5 | $7,473 |
| Novartis | 6 | $6,774 |
| Johnson & Johnson | 4 | $6,023 |
| Sanofi-aventis U.S. LLC | 3 | $4,719 |
| Regeneron | 1 | $2,293 |
| Bristol Myers Squibb | 2 | $2,065 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,650 |
| Janssen Research & Development, LLC | 5 | $1,145 |
| Vertex | 2 | $613 |
| ZOLL Medical Corporation | 1 | $600 |
| Tersera Therapeutics LLC | 1 | $550 |
| Dr.reddy's Laboratories,inc. | 1 | $548 |
| Genentech USA, Inc. | 2 | $208 |
| Genetix Biotherapeutics Inc | 1 | $73 |
| AstraZeneca | 1 | $32 |
| AbbVie | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$468,322 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
- Adam KittaiNew York$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.